Valuation: Brooks Laboratories Limited

Market Cap 1.99B 21.01M 18.76M 17.43M 15.86M 29.84M 30.37M 209M 81.94M 1.04B 78.86M 77.19M 3.32B P/E 2025
-28.6x
P/E 2026 4.45x
Enterprise Value 2.01B 21.21M 18.93M 17.6M 16.01M 30.11M 30.65M 211M 82.7M 1.05B 79.59M 77.91M 3.35B EV / Sales 2025
3.93x
EV / Sales 2026 1.3x
Free-Float
45.16%
Yield 2025 *
-
Yield 2026 -
09-16 Brooks Laboratories Limited Announces Resignation of Krutika Rane as Company Secretary and Compliance Officer (Key Managerial Personnel), Effective October 9, 2026 CI
08-13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
07-17 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-18 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/10/25 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/08/25 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/05/25 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/02/25 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day-4.05%
1 week-2.72%
Current month+21.09%
1 month+7.10%
3 months-2.24%
6 months-6.24%
Current year-15.69%
1 week 63.3
Extreme 63.3
73.45
1 month 52.97
Extreme 52.97
75.6
Current year 36.3
Extreme 36.3
82.44
1 year 36.3
Extreme 36.3
125.22
3 years 36.3
Extreme 36.3
198.86
5 years 36.3
Extreme 36.3
198.86
10 years 13.85
Extreme 13.85
198.86
Manager TitleAgeSince
Chief Executive Officer 58 22/01/2002
Chief Executive Officer - 31/05/2026
President 58 22/08/2023
Director TitleAgeSince
Director/Board Member 53 22/11/2022
Director/Board Member 62 09/09/2010
Director/Board Member - 22/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
-4.05%-2.72%-45.15%-39.34% 21.9M
+0.98%+7.64%+54.91%+105.85% 1,116B
+1.50%-1.90%+33.50%+62.81% 610B
+0.32%+3.39%+26.00%+94.15% 501B
+1.15%+1.09%+75.38%+41.33% 358B
-0.13%+5.56%+32.39%+49.79% 366B
-0.95%+4.65%+19.46%+42.94% 288B
-2.11%+3.82%-0.78%+13.53% 261B
+0.47%+5.36%+47.76%+52.36% 235B
-0.79%+3.41%+32.65%+97.39% 195B
Average -0.41%+4.88%+27.61%+52.08% 392.98B
Weighted average by Cap. +0.37%+4.93%+39.84%+72.21%

Financials

2025 2026
Net sales 826M 8.72M 7.78M 7.23M 6.58M 12.37M 12.6M 86.86M 33.99M 431M 32.71M 32.02M 1.38B 857M 9.05M 8.08M 7.51M 6.83M 12.85M 13.08M 90.21M 35.29M 447M 33.97M 33.25M 1.43B
Net income -99.67M -1.05M -939K -873K -794K -1.49M -1.52M -10.49M -4.1M -52M -3.95M -3.87M -166M 246M 2.6M 2.32M 2.15M 1.96M 3.68M 3.75M 25.87M 10.12M 128M 9.74M 9.53M 410M
Net Debt 75.39M 796K 711K 660K 601K 1.13M 1.15M 7.93M 3.1M 39.34M 2.99M 2.92M 126M 18.44M 195K 174K 161K 147K 276K 281K 1.94M 759K 9.62M 731K 715K 30.78M
Projected Income Statement - Annual - Brooks Laboratories Limited
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company. The Company specializes in supplying pharmaceutical products to government bodies, healthcare institutions, and large organizations. It operates through two segments, which include manufacturing and trading. The manufacturing segment comprises its own manufacturing operations and loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries. The trading segment comprises principal-to-principal trading activities in pharmaceutical products, ingredients, and intermediaries. Its General Products offerings include Liquid Injection (Ampoules), Liquid Injection (Vials), Dry Powder Injections (Vials), Lyophilised Injections, Eye/Ear Drops, and Nasal Drops. The Company's Critical Care Division (CCD), operates through a robust distribution network, delivering injectables to hospitals and healthcare institutions across India.
Employees
347
Date Price Change Volume
16/10/26 ₹67.57 -4.05% 122,176
15/10/26 ₹70.42 +2.47% 294,417
14/10/26 ₹68.72 +6.11% 215,139
13/10/26 ₹64.76 -1.19% 223,762
12/10/26 ₹65.54 -6.54% 160,788
  1. Stock Market
  2. Stocks
  3. BROOKS Stock